Patents Examined by Tomas Friend
  • Patent number: 6461813
    Abstract: The invention related to novel methods of detecting alterations in cell cycle regulation in a cell or a cell population and screening for agents capable of modulating cell cycle regulation through the use of multiparameter assays and a fluorescence-activated cell sorter (FACS) machine.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: October 8, 2002
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: James Lorens
  • Patent number: 6458923
    Abstract: The substitution of the L-Pro at the 7-position of the peptide hormone bradykinin or other substituted analogs of bradykinin with an isoquinoline derivative which converts bradykinin agonists into bradykinin antagonists. The invention further includes the novel 7-position modified bradykinin antagonists which increase enzyme resistance, antagonist potency, and/or specificity of the new bradykinin antagonists. The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected as by insect bites.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: October 1, 2002
    Assignee: Scios Inc.
    Inventor: Donald James Kyle
  • Patent number: 6448091
    Abstract: Methods and apparatus for performing a binding assay for an analyte of interest present in a sample are described. The methods include the steps of: forming a composition containing the sample, an assay-performance-substance which contains a component linked to a label compound capable of chemiluminescing when triggered, and a plurality of particles capable of specifically binding with the analyte and/or the assay-performance-substance; incubating the composition to form a complex which includes a particle and the labeled component; collecting the complex in a collection zone; introducing into the collection zone a trigger capable of triggering the label such that the label luminesces; and measuring the emitted luminescence to measure the presence of the analyte of interest in the sample.
    Type: Grant
    Filed: November 7, 1994
    Date of Patent: September 10, 2002
    Assignee: IGEN International, Inc.
    Inventors: Richard J. Massey, Gary F. Blackburn, Elizabeth W. Wilkins, Haresh P. Shah
  • Patent number: 6410246
    Abstract: A highly diverse library of yeast expression vectors encoding a library of fusion proteins such as antibodies is provided. The yeast expression vector formed in the library comprises: a first nucleotide sequence encoding a first polypeptide subunit; a second nucleotide sequence encoding a second polypeptide subunit; and a linker sequence encoding a linker peptide that links the first nucleotide sequence and the second nucleotide sequence. The first polypeptide subunit, the second polypeptide subunit, and the linker polypeptide are expressed as a single fusion protein within the library of fusion proteins. The first and second nucleotide sequences each independently varies within the library of expression vectors. The library of fusion proteins expressed by the library expression vectors can be used for screening against target molecules such as proteins, peptides, DNAs and small molecules in vitro and in vivo.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: June 25, 2002
    Assignee: Genetastix Corporation
    Inventors: Li Zhu, Shaobing Benjamin Hua
  • Patent number: 6406863
    Abstract: Compostions, kits and methods are provided for generating highly diverse libraries of proteins such as antibodies via homologous recombination in vivo, and screening these libraries against protein, peptide and nucleic acid targets using a two-hybrid method in yeast.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: June 18, 2002
    Assignee: GeneTastix Corporation
    Inventors: Li Zhu, Shaobing Benjamin Hua
  • Patent number: 6403605
    Abstract: The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and go cats. In an alternative embodiment, the present invention provides a method for the prophylactic treatment of long-term tissue degradation in the genital organs comprising the administration to a mammal of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: June 11, 2002
    Assignee: Queen's University at Kingston
    Inventors: Jeremy P. W. Heaton, Michael A. Adams